EATG » Hepatitis

Hepatitis

VBI Vaccines to advance Phase 3 study for Sci-B-Vac

VBI Vaccines announces FDA acceptance of Investigational New Drug Application for Sci-B-Vac® Phase 3 clinical program -- Sci-B-Vac® is a third-generation hepatitis B vaccine, approved for use in Israel and…

Immune response to hepatitis B vaccination in HIV-positive individuals with isolated anti-HBc

Results of a prospective Italian study Abstract Background and aim Antibodies against hepatitis B core antigen (anti-HBc) are found in 14–44% of patients with HIV infection, but it is still…

Risk of HBV reactivation low in DMARD users

More common with chronic versus resolved infection Hepatitis B virus (HBV) reactivation was unlikely in patients receiving disease-modifying antirheumatic drugs (DMARDs) whose HBV infection had resolved, according to a meta-analysis.…

Higher FIB-4 index in patients with HBV linked to increased HCC risk

In a cohort of patients with chronic hepatitis B without cirrhosis, the risk for hepatocellular carcinoma was significantly higher among those with a FIB-4 index over 1.29, according to recently…

The availability of direct-acting antivirals is reducing disparities in the uptake of hepatitis C treatment

Improvement in treatment access for people with HIV co-infection An analysis from British Columbia, Canada shows that older people, individuals with HIV co-infection, people with cirrhosis and – to some…

Continuum of hepatitis C care in France: A 20-year cohort study

Abstract Background Hepatitis C virus (HCV)-infected patients require a specific continuum of care (CoC) from HCV screening to treatment. We assessed CoC of HCV-infected patients in a longitudinal study. Methods…

Liver cancer risks not affected by hepatitis C eliminating therapy

Hepatitis C virus (HCV) patients faced a similar risk of developing liver cancer whether they eradicated the virus with direct-acting antiviral (DAA) drugs or interferon therapy, researchers in Japan found.…

New WHO guidelines for hepatitis B virus vaccine

The World Health Organization (WHO) issued updated recommendations for the use of the hepatitis B virus (HBV) vaccine, including a WHO report containing excerpts of the new recommendations that was…

HBV surface antibody reduces risk for reactivation during chemotherapy

In a recent meta-analysis of patients with resolved hepatitis B who underwent chemotherapy for hematological malignancies, the presence of positive antibodies to HBV surface antigen, or anti-HBs, was correlated with…

AAP recommends newborn hepatitis B vaccine by 24 hours of age

New recommendations from the American Academy of Pediatrics (AAP) say medically stable newborns weighing 2000 g or more should receive their first dose of the hepatitis B vaccine within the…